Skip to main
CGON
CGON logo

CGON Stock Forecast & Price Target

CGON Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 55%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

CG Oncology Inc. is poised for significant growth, with anticipated launch sales of its candidate, cretostimogene grenadenorepvec, beginning in 2026 and projected to reach approximately $2.6 billion by 2034, highlighting strong market potential driven by premium pricing strategies. The therapy addresses a critical unmet need for innovative treatments that could lower disease recurrence and enhance patient quality of life, suggesting a favorable reception among healthcare professionals and patients. Additionally, the promising clinical data supporting Creto’s efficacy and durability, alongside regulatory fast-tracking, underscores the company’s readiness for commercialization and positions it competitively in the expanding non-muscle invasive bladder cancer market.

Bears say

CG Oncology's stock outlook appears negative due to several significant risks associated with its clinical trials and overall market competitiveness. The potential for negative trial results, coupled with slower-than-expected enrollment and regulatory challenges, could hinder the timely commercialization of its bladder cancer therapies, thereby limiting market potential. Additionally, concerns regarding inadequate differentiation from existing therapies, such as Zaltrap's comparison to Avastin, raise questions about payer reimbursement sustainability, further compounding the challenges for CG Oncology's financial performance.

CGON has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 55% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CG oncology Inc (CGON) Forecast

Analysts have given CGON a Buy based on their latest research and market trends.

According to 11 analysts, CGON has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $62.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $62.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CG oncology Inc (CGON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.